Each of us is already a Migraine superhero. Like every great superhero, we fight a powerful enemy every day. It's called Migraine.

Tammy Rome, LPC is a licensed, board-certified NBCC counselor. She's also an associate member of both the American Headache Society and the International Headache Society. Tammy offers behavioral telehealth services to clients with migraine and other headache disorders.

In her role as President of Cluster Headache Support Group, Tammy advocates for migraine and cluster patients throughout the year. In February, she travels to Washington, D.C for "Headache on the Hill." Since its inception in 2012, she has accepted the Social Media Challenge for Migraine and Headache Awareness Month.  She also volunteers for the Runnin’ for Research 5-K each fall.

You can read more of Tammy’s work on her website. Follow her on Twitter or view her professional profile on LinkedIn.

Emgality™ Approved for Migraine Prevention in Adults

It's good news for Migraine patients as Eli Lilly and Company's Emgality™ (galcanezumab-gnlm) became the third new CGRP monoclonal antibody approved by the FDA for Migraine Prevention in Adults. With Emgality™ approved for Migraine prevention, patients have choices of preventive treatments were developed specifically for Migraine.Read More →
Side-by-Side Comparison of Aimovig, Ajovy, and Emgality

Comparing CGRP blockers is the next big challenge for Migraine patients. Now that we have three new preventive options specifically designed for Migraine, we’re faced with that all-important question: Which one should we choose: Aimovig, Ajovy, or Emgality?Read More →
NIH Grant Awarded for Development of New Migraine Treatment

NIH awards grant to CerSci Therapeutics for a preclinical trial to explore the development of a potentially new Migraine treatment blocking the free radical, peroxynitrite. This is just the first of many new studies we can expect as researchers work to develop better, safer treatments for Migraine.Read More →